Regeneron Pharmaceuticals Inc (REGN) : Genesee Valley Trust Co scooped up 61 additional shares in Regeneron Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 3,005 shares of Regeneron Pharmaceuticals Inc which is valued at $1,247,345.Regeneron Pharmaceuticals Inc makes up approximately 0.81% of Genesee Valley Trust Co’s portfolio.
Other Hedge Funds, Including , Conning reduced its stake in REGN by selling 90 shares or 4.41% in the most recent quarter. The Hedge Fund company now holds 1,950 shares of REGN which is valued at $809,426. Regeneron Pharmaceuticals Inc makes up approx 0.03% of Conning’s portfolio.Newsquare Capital reduced its stake in REGN by selling 2 shares or 12.5% in the most recent quarter. The Hedge Fund company now holds 14 shares of REGN which is valued at $5,811.Nikko Asset Management Americas boosted its stake in REGN in the latest quarter, The investment management firm added 400 additional shares and now holds a total of 1,000 shares of Regeneron Pharmaceuticals Inc which is valued at $384,700. Regeneron Pharmaceuticals Inc makes up approx 0.04% of Nikko Asset Management Americas’s portfolio.Creative Planning boosted its stake in REGN in the latest quarter, The investment management firm added 4,135 additional shares and now holds a total of 14,734 shares of Regeneron Pharmaceuticals Inc which is valued at $5,370,543. Regeneron Pharmaceuticals Inc makes up approx 0.04% of Creative Planning’s portfolio.
Regeneron Pharmaceuticals Inc opened for trading at $411.33 and hit $425.88 on the upside on Friday, eventually ending the session at $425.12, with a gain of 3.43% or 14.08 points. The heightened volatility saw the trading volume jump to 13,70,477 shares. Company has a market cap of $44,671 M.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.55. The company had revenue of $1201.00 million for the quarter, compared to analysts expectations of $1178.39 million. The company’s revenue was up 38.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.88 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.